Akero Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for patients with serious metabolic diseases. The company’s lead candidate, efruxifermin, is an Fc-fusion analog of fibroblast growth factor 21 (FGF21) designed to improve lipid metabolism, reduce liver fat, and address the underlying drivers of nonalcoholic steatohepatitis (NASH). Akero’s research platform leverages engineered hormone analogs to target key metabolic pathways implicated in NASH, type 2 diabetes, and other related disorders.
In addition to its efruxifermin program, Akero maintains a pipeline of next-generation FGF21-based molecules at various stages of preclinical and clinical development. The company’s approach aims to balance efficacy and tolerability by optimizing pharmacokinetics and receptor engagement, with the goal of delivering durable improvements in liver histology and metabolic function. Akero has reported promising data from Phase 2 studies in NASH, demonstrating reductions in hepatic fat content, improvements in fibrosis markers, and favorable safety profiles.
Founded in 2016 and headquartered in Boston, Massachusetts, Akero Therapeutics operates within major biotech hubs and collaborates with academic institutions and strategic partners worldwide. The company’s leadership team combines expertise in endocrinology, hepatology, and drug development, with a focus on advancing therapies that address the growing global burden of metabolic liver disease. Akero is committed to rigorous clinical evaluation and aims to bring first-in-class or best-in-class treatments to patients with limited therapeutic options.
AI Generated. May Contain Errors.
Free AKRO Stock Alerts